Black Hawk Acquisition Corporation news covers SPAC-related corporate developments, including proxy amendments, trust-account extension terms, shareholder voting matters, governance changes, and capital-structure updates. Company announcements have also addressed board appointments and the mechanics of extending the deadline to complete an initial business combination.
As a blank-check issuer, Black Hawk's recurring news is tied to its securities, trust account, redemption framework, sponsor-related capital actions, and merger-related disclosure categories rather than operating revenue from products or services.
Black Hawk Acquisition Corporation (BKHAU) announced approximately $25.15 million in redemption payments tied to its proposed business combination with Vesicor Therapeutics. Holders of 2,089,162 Class A ordinary shares eligible for redemption exercised their rights. The redemptions do not affect other issued and outstanding Class A ordinary shares. Following the redemptions, Black Hawk expects approximately 2.06 million Class A ordinary shares outstanding, including shares not subject to redemption.
The estimated remaining trust balance is $420,377, subject to final reconciliation and adjustment. Upon closing, the combined company is expected to trade on Nasdaq as VESI. Vesicor is a preclinical-stage biotechnology company developing p53-based cancer therapeutics; its lead candidate, ecm-RV/p53, is designed to restore tumor suppression in advanced solid tumors.
Vesicor Therapeutics (Nasdaq: BKHAU) named Michael Tolentino, M.D., as CEO effective March 17, 2026, with Founder Luo Feng, Ph.D., moving to Chief Scientific Officer. The company said it intends to complete a proposed de-SPAC merger with Black Hawk Acquisition Corporation and advance IND-enabling studies aiming for an IND submission in 2027.
The appointment highlights Tolentino’s 20+ years in biotech, prior company exits and drug development experience, which Vesicor cites as supporting efforts to accelerate regulatory progress and shareholder value creation.
Black Hawk Acquisition Corporation (NASDAQ: BKHAU) has filed a supplement to its definitive proxy statement to modify the Trust Amendment Proposal. The company has revised the extension fee structure for its business combination deadline. Instead of the previous variable fee of $0.033 per outstanding public share, the company will now deposit a fixed amount of $150,000 for each one-month extension to complete an initial business combination.
This amendment removes the company's discretion in determining the deposit amount and provides greater transparency regarding extension obligations.
Vesicor Therapeutics and Black Hawk Acquisition have signed a business combination agreement to create a biotechnology company focused on p53-based cancer therapeutics. The deal values Vesicor at $70 million pre-money equity value and is expected to complete in Q4 2025.
Founded in 2008 by Dr. Luo Feng, Vesicor's main product candidate is ecm-RV/p53, a genetically engineered microvesicle loaded with p53 mRNA. While unapproved in the US and Japan, the drug has been administered to patients with advanced breast, pancreatic, prostate, lung, and colorectal cancer in Tokyo since 2018 under Japan's Advanced Medical Care B program.
Key transaction points:
- Vesicor will become a wholly-owned subsidiary of Black Hawk
- Existing shareholders will roll over 100% of their equity
- Six-month lock-up period for certain shareholders
- Combined company will be listed on Nasdaq
Vesicor plans to begin US preclinical testing and submit an FDA investigational new drug application in 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.